Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects
Status:
Completed
Trial end date:
2018-01-18
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to investigate the safety and tolerability of BAY
1841788 in Japanese subjects with metastatic castration-resistant prostate cancer (mCRPC) and
the PK of BAY 1841788 and its major metabolite BAY 1896953.